Compounds · Metabolic & weight · Treatment of obesity and type 2 diabetes
Mazdutide (LY3305677 / IBI362)
LY3305677, IBI362, OXM3
Dual GLP-1/glucagon receptor agonist (LY3305677/IBI362) discovered in 2018, combining GLP-1 and glucagon signaling for stronger metabolic effects than single-receptor drugs. In Phase 3 trials for obesity and type 2 diabetes, showing notable weight loss and glycemic improvement.
1.5 → 6 mg weekly, titrated
Research score 85/100. Reference only, not a prescription.
- Appetite Suppression
- Metabolic Enhancement
- Blood Sugar Control
- GLP-1 Agonist
- Weight Loss
- Insulin Regulation
- US status
- Investigational
- Approval
- Phase 3 Clinical Trial
- Evidence
- Investigational GLP-1R and GCGR dual agonist. Shows significant weight loss and glycemic control in Type 2 diabetes and obesity trials.
- Research score
- 85 / 100
- Indication
- Obesity/Weight Management
- Origin
- China
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 receptor activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and promotes satiety, while glucagon receptor activation raises energy expenditure and lipid metabolism; structural changes resist DPP-4 breakdown and bind albumin for once-weekly dosing.
Safety file
Mostly mild-to-moderate GI effects (nausea, diarrhea, vomiting), transient; some increased heart rate; low rate of serious adverse events, with no severe hypoglycemia in non-diabetics.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
- Headache
Reconstitution
| Vial | 1 mL water | 2 mL water |
|---|---|---|
| 10 mg | 10 mg/mL | 5 mg/mL |
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous
Standard titration (once weekly, subcutaneous)
- Weeks 1 to 4: 1.5 mg
- Weeks 5 to 8: 3 mg
- Weeks 9 to 12: 4.5 mg
- Week 13 onward: 6 mg as the maintenance dose
- (A simpler 2 mg, then 4 mg, then 6 mg version on the same 4-week steps is also used.)
Dosing detail
- Start at 1.5 mg and step up every 4 weeks. Going too fast is the top reason people quit, almost always from nausea.
- Maintenance is commonly 6 mg weekly. China approved it at 4 mg and 6 mg in 2025 (brand name Xinermei), and a higher 9 mg dose (titrated 3, 6, 9) is under review there for severe obesity.
- Some step down to 4.5 mg or 3 mg once at goal to hold results with fewer side effects.
- One consistent day per week.
Duration
- Titrate over 12 to 16 weeks, then maintain. Like the other GLP-1 class drugs, stopping tends to bring weight back.
Notes
- A GLP-1 / glucagon dual agonist, so appetite suppression plus a metabolic bump are the headline effects.
- Inject subcutaneously and rotate sites.
- GI effects are dose-related and ease with slow titration.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.